Metabolic Dysfunction-Associated Steatotic Liver Disease

Increased intake of dietary niacin may reduce the risk for all-cause mortality but not cardiovascular disease-related mortality among patients with metabolic dysfunction-associated steatotic liver disease, data showed.

Chronic liver disease is the ninth leading cause of death in the United States, independent of liver cancer. According to the CDC, only 1.8% of adult Americans have a diagnosis of chronic liver disease, which translates to 4.5 million people.

Finding adequate providers with the expertise to treat the growing population of patients with chronic liver diseases, including metabolic dysfunction-associated steatotic liver disease, is a challenging but important endeavor.

Women with concurrent metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease had an 83% greater risk for all-cause mortality than men and those with ALD alone had 160% greater risk, data showed.

A $37 million study led by Newcastle University, University of Edinburgh and Boehringer Ingelheim is underway to address the “urgent need” for anti-scarring therapies for individuals with liver disease.

Vibration-controlled transient elastography and serum-based noninvasive tests show a significant discrepancy in detecting liver fibrosis, according to study findings published in Obesity.

Chronic hepatitis B virus infection was positively linked with severe hepatic necroinflammation in children with metabolic dysfunction-associated steatotic liver disease but did not appear to affect hepatic fibrosis, according to data.

Screening for liver fibrosis was associated with improved self-reported alcohol consumption, diet, exercise and weight after 6 months among patients at risk for liver disease, with lifestyle changes persisting through 2 years.

Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists were associated with lower risk for cardiovascular events in type 2 diabetes, with or without metabolic dysfunction-associated steatotic liver disease.

BOSTON — In this video, Rohit Loomba, MD, MHSc, discusses data supporting once-monthly dosing of BOS-580, an investigational, long-acting fibroblast growth factor-21 analog for treatment of metabolic dysfunction-associated steatohepatitis.